Nuvation Bio to present subgroup analyses from TRUST-I, TRUST-II taletrectinib studies in ROS1+ NSCLC at WCLC 2026PUBT·1 day ago, 07:06 AMNUVB-1.09%
Mixed Signals: How 10 Cross-Sector Equities Highlight Shifting Capital StrategiesGlobal Report·Aug 2 at 04:13 AMACGL-0.43%SATA+0.29%
The Island of Misfit Toys: From AI Cooling to TikTok Cash, Who's Actually Building a Business?Global Report·Jul 30 at 04:14 AMNRGV-7.67%SRXH+1.46%
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | NUVB Stock NewsStockTitan·Jul 22 at 07:05 AMNUVB-1.09%
AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Mondaybenzinga_article·Jul 20 at 09:08 AMNUVB-1.09%IREN-4.80%
Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma programPUBT·Jul 20 at 07:18 AMNUVB-1.09%
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma | NUVB Stock NewsStockTitan·Jul 19 at 11:00 PMNUVB-1.09%
Is Nuvation Bio (NUVB) Fairly Valued Following UK Taletrectinib Filing Progress?Simplywall·Jul 13 at 04:12 PMNUVB-1.09%
